Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To determine whether the primary endpoint: the composite success rate, defined as the
proportion of patients who are alive at day 100; and are without grade 3-4 Graft versus Host
Disease (GVHD); and are without grade 4 toxicity (unrelated to infection); and have
engrafted, is likely to be at least 40%.
Secondary Objectives:
1. To determine the cumulative incidence of chronic graft versus host disease.
2. To determine the overall and disease free survival.